<DOC>
	<DOCNO>NCT00066482</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effect body combine cyclophosphamide cisplatin , etoposide , bleomycin treat child newly diagnose malignant germ cell tumor brain gonad .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Newly Diagnosed Malignant Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose toxicity profile cyclophosphamide combination bleomycin , etoposide , cisplatin pediatric patient newly diagnose high-risk extracranial , extragonadal malignant germ cell tumor . - Determine response rate patient treat regimen . OUTLINE : This pilot , multicenter , dose-escalation study cyclophosphamide . - Induction therapy : Patients receive bleomycin IV 10-20 minute day 1 , etoposide IV 1 hour cisplatin IV 4 hour day 1-5 , cyclophosphamide IV 1 hour day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 6 continue blood count recover . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos cyclophosphamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients evaluate 4 course therapy . Patients partial response stable disease undergo second-look surgery , receive 2 course induction therapy , re-evaluated . Patients achieve complete response ( CR ) total 6 course may undergo third surgery . Patients still tumor remove remove study therapy . Patients achieve CR anytime follow . Patients follow monthly 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 6-18 patient accrue study within 1.3 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose extracranial germ cell tumor , include 1 follow type : Yolk sac carcinoma ( endodermal sinus tumor ) Embryonal carcinoma Choriocarcinoma Teratoma mixed malignant element ( malignant teratoma ) Highrisk disease , define stage III IV extragonadal germ cell tumor Must enrol study within 21 day diagnostic surgical procedure PATIENT CHARACTERISTICS : Age 21 ( original diagnosis ) Performance status ECOG 02 Karnofsky 50100 % ( patient 16 year age ) Lansky 50100 % ( patient 16 year age ) Life expectancy At least 2 month Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 10.0 g/dL ( transfusion allow ) Hepatic Not specify Renal Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min OR Creatinine base age follow : No great 0.8 mg/dL ( 5 year ) No great 1.0 mg/dL ( 610 year ) No great 1.2 mg/dL ( 1115 year ) No great 1.5 mg/dL ( 15 year ) Pulmonary FEV_1/FVC great 60 % OR Children uncooperative must meet following criterion : No dyspnea rest No exercise intolerance Pulse oximetry great 94 % Other Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
</DOC>